Alternative splicing of HER2: a novel mediator of EGFR TKI resistance

被引：1
|
作者：
Yochum, Zachary A. [1 ,2 ]
Villaruz, Liza C. [1 ]
机构：
[1] UPMC Hillman Canc Ctr, Dept Med, Div Hematol Oncol, Pittsburgh, PA USA
[2] Univ Pittsburgh, Sch Med, Med Scientist Training Program, Pittsburgh, PA USA
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2020年 / 9卷 / 04期
关键词：
CELL LUNG-CANCER; PHASE-III; BREAST-CANCER; OPEN-LABEL; 1ST-LINE; AMPLIFICATION; OSIMERTINIB; MUTATION;
D O I：
10.21037/tlcr-20-618
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1606 / 1612
页数：7
相关论文
共 50 条
  • [41] HER2 expression as a potential marker for response to therapy targeted to the EGFR
    D R Emlet
    R Schwartz
    K A Brown
    A A Pollice
    C A Smith
    S E Shackney
    British Journal of Cancer, 2006, 94 : 1144 - 1153
  • [42] HER2 expression as a potential marker for response to therapy targeted to the EGFR
    Emlet, DR
    Schwartz, R
    Brown, KA
    Pollice, AA
    Smith, CA
    Shackney, SE
    BRITISH JOURNAL OF CANCER, 2006, 94 (08) : 1144 - 1153
  • [43] HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts
    Eriksson, Pontus
    Sjodahl, Gottfrid
    Chebil, Gunilla
    Liedberg, Fredrik
    Hoglund, Mattias
    ONCOTARGET, 2017, 8 (30) : 48905 - 48914
  • [44] Novel curcumin analogs to overcome EGFR-TKI lung adenocarcinoma drug resistance and reduce EGFR-TKI-induced GI adverse effects
    Wada, Koji
    Lee, Jen-Yi
    Hung, Hsin-Yi
    Shi, Qian
    Lin, Li
    Zhao, Yu
    Goto, Masuo
    Yang, Pan-Chyr
    Kuo, Sheng-Chu
    Chen, Hui-Wen
    Lee, Kuo-Hsiung
    BIOORGANIC & MEDICINAL CHEMISTRY, 2015, 23 (07) : 1507 - 1514
  • [45] Case report: HER2 amplification as a resistance mechanism to crizotinib in NSCLC with MET exon 14 skipping
    Ding, Guanggui
    Wang, Jian
    Ding, Peikun
    Wen, Yuxin
    Yang, Lin
    CANCER BIOLOGY & THERAPY, 2019, 20 (06) : 837 - 842
  • [46] Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report
    Zhang, Ping
    Nie, Xin
    Wang, Bing
    Li, Lin
    THORACIC CANCER, 2018, 9 (12) : 1774 - 1777
  • [47] Comparison of Central HER2 Testing With Quantitative Total HER2 Expression and HER2 Homodimer Measurements Using a Novel Proximity-Based Assay
    Huang, Weidong
    Reinholz, Monica
    Weidler, Jodi
    Lie, Yolanda
    Paquet, Agnes
    Whitcomb, Jeannette
    Lingle, Wilma
    Jenkins, Robert B.
    Chen, Beiyun
    Larson, Jeffrey S.
    Tan, Yuping
    Sherwood, Thomas
    Bates, Michael
    Perez, Edith A.
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2010, 134 (02) : 303 - 311
  • [48] The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer
    Nagasaka, Misako
    Singh, Vijendra
    Baca, Yasmine
    Sukari, Ammar
    Kim, Chul
    Mamdani, Hirva
    Spira, Alexander, I
    Uprety, Dipesh
    Bepler, Gerold
    Kim, Edward S.
    Raez, Luis E.
    Pai, Sachin Gopalkrishna
    Ikpeazu, Chukwuemeka
    Oberley, Matthew
    Feldman, Rebecca
    Xiu, Joanne
    Korn, W. Michael
    Wozniak, Antoinette J.
    Borghaei, Hossein
    Liu, Stephen, V
    CLINICAL LUNG CANCER, 2022, 23 (01) : 52 - 59
  • [49] ErbB2 (HER2)-positives MammakarzinomResistenzmechanismenErbB2 (HER2) positive breast cancer Mechanisms of resistance
    K. Kast
    W. Distler
    Der Gynäkologe, 2010, 43 (7): : 574 - 578
  • [50] EGFR, HER2 and HER3 expression in esophageal primary tumours and corresponding metastases
    Wei, Qichun
    Chen, Lirong
    Sheng, Liming
    Nordgren, Hans
    Wester, Kenneth
    Carlsson, Jorgen
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2007, 31 (03) : 493 - 499
12345